Advancements in GLP-1s and Wegovy show promise in treating heart disease and obesity

Eli Lilly and Novo Nordisk are quietly preparing to build comprehensive cardiovascular franchises using their lucrative treatments for diabetes and obesity. Both companies have started publicly discussing their plans to test their GLP-1s in various diseases, including heart and kidney disease, with 2024 being a pivotal year for these drugs. Novo's Phase III SELECT trial showed a 20% reduced risk of major cardiovascular events in adults with type 2 diabetes or obesity, highlighting the broader potential of GLP-1s.